S
68.59
-0.07 (-0.10%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Sol-Gel Technologies Ltd. | 混合的 | 看涨 |
AIStockmoo 评分
0.4
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 1.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| 宏观环境 | -0.3 |
| AI Insight | NA |
| 平均 | 0.44 |
|
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 70.00% |
| 机构持股比例 | 24.29% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Navellier & Associates Inc | 30 Jun 2026 | 5,785 |
该时间范围内无数据。
该时间范围内无数据。
投资组合